Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7656896 | 0.80 | PARP1 (0.37) | PARP1MAPK8 | |
| SCHEMBL7220903 | 0.79 | PARP1 (0.36) | PARP1 | |
| SCHEMBL7216572 | 0.79 | PARP1 (0.39) | PARP1 | |
| SCHEMBL7214410 | 0.74 | PARP1 (0.54) | PARP1MAPK8KDM4E | |
| SCHEMBL30657976 | 0.68 | TTR (0.40) | MAPK8 | |
| SCHEMBL9141316 | 0.63 | MAPT (0.43) | KDM4E | |
| SCHEMBL19437350 | 0.62 | PARP1 (0.68) | PARP1 | |
| SCHEMBL19437294 | 0.62 | PARP1 (0.57) | PARP1 | |
| SCHEMBL30569549 | 0.60 | CTNNB1 (0.49) | KDM4E | |
| SCHEMBL29070071 | 0.60 | CTNNB1 (0.49) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576766-B1 | Competitive binding of phosphotyrosine-containing protein; veterinary medicine | ARIAD PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-6573295-B2 | Treating proliferative diseases, cancer, restenosis, osteoporosis, inflammation, aIlergies, or cardiovascular disease. | ARIAD PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-6482852-B2 | UE TREATING PROLIFERATIVE DISEASE, CANCER, RESTENOSIS, OSTEOPOROSIS, INFLAMMATION, ALLERGIES, OR CARDIOVASCULAR DISEASE; INHIBITION OF SH2-MEDIATED SIGNALING | ARIAD PHARMACEUTICALS, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | ARIAD PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020062031-A1 | Bicyclic signal transduction inhibitors, compositions containing them & uses thereof | SHAKESPEARE WILLIAM C (US) | 2002-05-23 | — | — | US | disclosed |
| EP-1129068-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITION CONTAINING THEM AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027802-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM & USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020062031-A1 | Bicyclic signal transduction inhibitors, compositions containing them & uses thereof | ACP1, SRC, PPM1G | PARP1 2454/4885MAPK8 83/4885KDM4E 2585/4885 |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | GRB2, LCK, PTK2 | PARP1 3059/4885MAPK8 115/4885KDM4E 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.